Get the Stockscreener App
14.07
2.36%
-0.34
Novocure Ltd stock is traded at $14.07, with a volume of 1.29M.
It is down -2.36% in the last 24 hours and down -13.26% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$14.41
Open:
$14.41
24h Volume:
1.29M
Relative Volume:
0.76
Market Cap:
$1.64B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-9.1703
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
-3.50%
1M Performance:
-13.26%
6M Performance:
+11.49%
1Y Performance:
+0.29%
1-Day Range:
$13.88
$14.41
1-Week Range:
$13.76
$14.76
52-Week Range:
$9.82
$21.45
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.07 | 1.64B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-26 | Resumed | JP Morgan | Neutral |
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure (NVCR) Stock Looks Cheap On Sales But Weak On Adoption Risk - simplywall.st
NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026 - Kalkine Media
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com South Africa
NovoCure at Wells Fargo healthcare conference: launch momentum builds - Investing.com
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com India
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com UK
Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026 - marketscreener.com
Timothy Scannell retires from NovoCure board, seat vacated Sept 2, 2026 - TradingView
NovoCure (NASDAQ: NVCR) director steps down with no dispute - Stock Titan
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Yahoo Finance
NOVOCURE LTD (NVCR) Stock Chart - ChartMill
Cash flow from operating activities of NovoCure Ltd. – HAM:038 - TradingView
Net debt of NovoCure Ltd. – HAM:038 - TradingView
NovoCure says cyberattack caused patient data exposure - Yahoo Finance
Basic earnings per share (basic EPS) of NovoCure Ltd. – HAM:038 - TradingView
NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk - simplywall.st
NewsNovocure discloses cyberattack exposing records of more than 1,400 US cancer patients - teiss
Novocure Announces Upcoming Investor Events - finance.yahoo.com
NovoCure (NASDAQ: NVCR) Data Breach Exposes IDs Linked to Over 1,400 U.S. Patient Records - Kalkine Media
Novocure Reveals Major Breach of Cancer Patient Records - sqmagazine.co.uk
Oncology firm Novocure says cyberattack exposed US patient records - CNA
NVCR Looks 3.4% Undervalued on GF Value™ Amid Cybersecurity Inci - GuruFocus
Novocure reports data access affecting patient IDs for 1,400+ U.S. records; no device access - TradingView
NovoCure cyber breach hits 1,400+ patient records - Stock Titan
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates? - simplywall.st
NovoCure Limited (NVCR) Stock Price & News - Syfe
Novocure Ltd (NVCR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
Novocure Ltd (NVCR) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors? - simplywall.st
A Look at NovoCure Ltd (NVCR) After 3.7% Decline -- GF Value $18 - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Down 4%What's Next? - MarketBeat
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice - Yahoo Finance
Novocure | 8-K: Current report - Moomoo
What’s Behind NovoCure (NVCR) Shares Climbing Today? - simplywall.st
What’s Behind NovoCure (NVCR) Shares Climbing Today? - simplywall.st
NVCR Q2 2026 Earnings: Loss Narrower Than Expected; Shares Slip 0.82Earnings Preview - vinanet.vn
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet - Yahoo Finance
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials ProgressHas The Bull Case Changed? - simplywall.st
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials ProgressHas The Bull Case Changed? - simplywall.st
First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR - marketbeat.com
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - simplywall.st
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - simplywall.st
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen - MarketBeat
Novocure Ltd (NVCR) Stock Analysis & Forecast - TradingKey
NovoCure Ltd (038.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Quantinno Capital Management LP Has $27.11 Million Stock Position in NovoCure Limited $NVCR - MarketBeat
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years - simplywall.st
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
| FRANCIS LEONARD | Officer |
Jun 04 '26 |
Proposed Sale |
17.93 |
34,273 |
614,635 |
0 |
| Hung David | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
20,465 |
| LEUNG GABRIEL | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
89,499 |
| Stafford Kristin | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
11,324 |
| Ocean Allyson J | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
11,324 |
| Scannell Timothy J | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
14,288 |
| HILLEMAN JERYL L | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
13,861 |
| VERNON W ANTHONY | Director |
Jun 02 '26 |
Sale |
15.77 |
2,945 |
46,445 |
197,657 |
| VERNON W ANTHONY | Director |
Apr 28 '26 |
Option Exercise |
11.39 |
21,500 |
244,885 |
200,602 |
4.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):